Latest & greatest articles for endometriosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on endometriosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on endometriosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for endometriosis

1. Elagolix (Orilissa) - for the treatment of moderate to severe pain associated with endometriosis

Elagolix (Orilissa) - for the treatment of moderate to severe pain associated with endometriosis Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs

2019 Health Canada - Drug and Health Product Register

2. Dysmenorrhea and Endometriosis in the Adolescent

Dysmenorrhea and Endometriosis in the Adolescent Dysmenorrhea and Endometriosis in the Adolescent - ACOG Menu ▼ Dysmenorrhea and Endometriosis in the Adolescent Page Navigation ▼ Number 760 Committee on Adolescent Health Care This Committee Opinion was developed by the American College of Obstetricians and Gynecologists’ Committee on Adolescent Health Care in collaboration with committee members Geri D. Hewitt, MD and Karen R. Gerancher, MD. This information is designed as an educational (...) accepted any commercial involvement in the development of the content of this published product. Dysmenorrhea and Endometriosis in the Adolescent ABSTRACT: Dysmenorrhea, or menstrual pain, is the most common menstrual symptom among adolescent girls and young women. Most adolescents experiencing dysmenorrhea have primary dysmenorrhea , defined as painful menstruation in the absence of pelvic pathology. When the patient’s history suggests primary dysmenorrhea, empiric treatment should be initiated. When

2019 American College of Obstetricians and Gynecologists

3. Transversus abdominis plane block under laparoscopic guide versus port-site local anaesthetic infiltration in laparoscopic excision of endometriosis: a double-blind randomised placebo-controlled trial

Transversus abdominis plane block under laparoscopic guide versus port-site local anaesthetic infiltration in laparoscopic excision of endometriosis: a double-blind randomised placebo-controlled trial To compare the efficiency of laparoscopically guided transversus abdominis plane block (LTAP) versus port-site local anaesthetic infiltration (LAI) in reducing postoperative pain following laparoscopic excision of endometriosis.A prospective, double-blind randomised controlled trial.A tertiary (...) referral centre for endometriosis and minimally invasive gynaecological surgery.Women undergoing laparoscopic excision of endometriosis from December 2015 through July 2016.Participants were randomised to receive: port-site infiltration with bupivacaine and placebo LTAP (LAI group, n = 21); placebo port-site infiltration and LTAP with bupivacaine (LTAP group, n = 24); placebo port-site infiltration and placebo LTAP (placebo group, n = 25).Post-operative pain at 2-4, 6-8, 10-12 and 24 hours, analgesic

2019 EvidenceUpdates

4. The prevalence of clinically-confirmed endometriosis: systematic review and meta-analysis

The prevalence of clinically-confirmed endometriosis: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

5. Traditional Chinese patent medicine for endometriosis: a network meta-analysis and systematic review

Traditional Chinese patent medicine for endometriosis: a network meta-analysis and systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

6. The impact of endometriosis on early pregnancy and that of pregnancy on endometriomas. A systemic review and meta-analysis.

The impact of endometriosis on early pregnancy and that of pregnancy on endometriomas. A systemic review and meta-analysis. Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

7. The effects of nutrition and lifestyle on endometriosis

The effects of nutrition and lifestyle on endometriosis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO

8. Comparisons of GnRH antagonist versus GnRH agonist protocols for endometriosis in patients undergoing IVF/ICSI: a systematic review and meta-analysis

Comparisons of GnRH antagonist versus GnRH agonist protocols for endometriosis in patients undergoing IVF/ICSI: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

9. Early life factors, in utero exposures and endometriosis risk: a meta-analysis

Early life factors, in utero exposures and endometriosis risk: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

10. Proteomics of endometriosis: a systematic review

Proteomics of endometriosis: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO

11. Diagnostic accuracy of per-operative laparoscopic imaging tools for the diagnosis of endometriosis

Diagnostic accuracy of per-operative laparoscopic imaging tools for the diagnosis of endometriosis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

12. Diagnosis and treatment options for extrapelvic endometriosis: systematic review

Diagnosis and treatment options for extrapelvic endometriosis: systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

13. Meta-analysis of treatment of endometriosis with Kuntai capsule combined with GnRH-a

Meta-analysis of treatment of endometriosis with Kuntai capsule combined with GnRH-a Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

14. Long-term GnRH agonist therapy before in vitro fertilization (IVF) for improving fertility outcomes in women with endometriosis [Cochrane protocol]

Long-term GnRH agonist therapy before in vitro fertilization (IVF) for improving fertility outcomes in women with endometriosis [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

15. A shift in evidence on outcomes for women undergoing laparoscopic surgery for endometriosis: a systematic review and meta-analysis

A shift in evidence on outcomes for women undergoing laparoscopic surgery for endometriosis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

16. The role of fertility preservation prior to endometriosis surgery

The role of fertility preservation prior to endometriosis surgery Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2019 PROSPERO

17. Renal Endometriosis: The Case of an Endometrial Implant Mimicking a Renal Mass (PubMed)

Renal Endometriosis: The Case of an Endometrial Implant Mimicking a Renal Mass Background: Endometriosis is a multifactorial benign disorder characterized by the abnormal presence of endometrial tissue in an extraendometrial site. Although extrapelvic endometriosis is uncommon, symptomatic involvement of the kidney is exceedingly rare. This benign disease can mimic several urologic processes, but because of its scarcity in clinical practice, it is seldom considered in the differential. Case (...) Presentation: In this report, we describe the case of a 45-year-old woman with flank pain and hematuria, who was found to have a left renal mass on cross-sectional imaging. After robotic partial nephrectomy, pathologic analysis revealed an endometrial implant within the renal parenchyma. Conclusion: This case of renal endometriosis highlights how this benign disease process can mimic several more sinister urologic processes.

Full Text available with Trip Pro

2018 Journal of endourology case reports

18. MRI-Ultrasound Fusion Imaging for Diagnosis of Deep Infiltrating Endometriosis – A Critical Appraisal (PubMed)

MRI-Ultrasound Fusion Imaging for Diagnosis of Deep Infiltrating Endometriosis – A Critical Appraisal It was the aim of our study to evaluate this procedure using pelvic anatomical landmarks in order to assess the accuracy of fusion imaging and to critically evaluate the applicability in daily practice.In a prospective, single center study, 10 patients with clinical signs of deep infiltrating endometriosis (DIE) were selected. We measured the distance between the landmark organ and the target

Full Text available with Trip Pro

2018 Ultrasound international open

19. Elagolix sodium (Orilissa) - For the management of moderate to severe pain associated with endometriosis

Elagolix sodium (Orilissa) - For the management of moderate to severe pain associated with endometriosis Drug Approval Package: Orilissa (elagolix sodium) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Orilissa (elagolix sodium) Company: AbbVie Inc. Application Number: 210450 Approval Date: 07/23/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF

2018 FDA - Drug Approval Package

20. Elagolix for Treating Endometriosis

Elagolix for Treating Endometriosis ©Institute for Clinical and Economic Review, 2018 Elagolix for Treating Endometriosis Final Evidence Report August 03, 2018 Prepared for ©Institute for Clinical and Economic Review, 2018 Page i Final Evidence Report– Elagolix for Treating Endometriosis ICER Staff/Consultants University of Colorado Skaggs School of Pharmacy Modeling Group* Steven J. Atlas, MD, MPH Director, Primary Care Research and Quality Improvement Network Massachusetts General Hospital (...) and Economic Review, 2018 Page ii Final Evidence Report– Elagolix for Treating Endometriosis About ICER The Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates medical evidence and convenes public deliberative bodies to help stakeholders interpret and apply evidence to improve patient outcomes and control costs. Through all its work, ICER seeks to help create a future in which collaborative efforts to move evidence into action provide

2018 California Technology Assessment Forum